





County of Los Angeles Department of Public Health, Substance Abuse Prevention and Control Program With

UCLA Integrated Substance Abuse Programs and the Pacific Southwest Addiction Technology Transfer Center

Presents a Special Training on:

Vaping, Fentanyl, and Methamphetamine, Oh My!
A Deep Dive into Emerging Drug Trends

Friday, December 13, 2019, 10:00 a.m. - 1:15 p.m.

County of Los Angeles Dept. of Public Health,
Substance Abuse Prevention and Control
The Alhambra Auditorium
1000 South Fremont Avenue, Alhambra, CA 91803

Featured Presenters:

Beth A. Rutkowski, MPH, Director of Training & Epidemiologist, UCLA Integrated Substance Abuse Programs, Co-Director Pacific Southwest Addiction Technology Transfer Center (HHS Region 9)

David Hindman, PhD, Chief, Clinical Standards and Training Unit Substance Abuse Prevention & Control

Provider Panel Representatives:

Shirley Summers, LCSW, President/CEO, Behavioral Health Services
Christopher Abernathy, MS, Senior Director of Treatment Services, Social Model Recovery Systems
John Smith, Ph.D, LCSW, Director of Education & Training, Social Model Recovery Systems

Description:

This Lecture Series presentation will provide a detailed review of local and national emerging drug trends. Epidemiological data on synthetic drugs, fentanyl, other synthetic opioids, marijuana, methamphetamine, cocaine, mixed opioids/stimulants and vaping (marijuana and nicotine) will be presented. The presentation will define key terms, describe the major classes of emerging drugs, present available data on the extent of use, and discuss the acute and chronic effects. The presentation will conclude with a discussion of treatment considerations and health concerns.

A panel discussion will follow this presentation featuring representatives from SAPC's specialty substance use disorder (SUD) treatment provider network. This portion of the presentation is intended to assist SUD providers in addressing real world concerns with emerging substances of abuse because they are constantly changing. Additionally, panelists will share their perspectives on the growing use of emerging drugs, as well as their efforts to implement evidence-based treatment options to assist in addressing the ongoing epidemic.

Objectives: At the end of this presentation, participants will be able to:

- 1) Describe the current information on the availability and patterns of emerging drug tends in the United States.
- 2) Identify the key characteristics and acute and chronic effects of synthetic drugs, most notably synthetic opioids (fentanyl), synthetic cannabinoids (spice) and synthetic cathinones (bath salts).
- 3) Identify the key characteristics and acute and chronic effects of mixed opioids and stimulants.
- 4) Explain strategies for communicating the dangers involved with the use of emerging drugs, including the current vaping lung illness epidemic.

Continuing Education:

The training course meets the qualifications for the provision of three (3.0) continuing education credits/ contact hours (CEs/CEHs). UCLA ISAP is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for LMFTs, LCSWs, LPCCs, and/or LEPs (Provider #64812). UCLA ISAP maintains responsibility for this program/course and its content. Course meets the qualifications for three (3.0) hours of continuing education credit for LMFTs, LCSWs, LPCCS, and LEPs as required by the California Board of Behavioral Sciences. UCLA ISAP is also an approved provider of continuing education for RADTs I/II, CADCs-CASs, CADCs I/II, CADCs-CSs, and LAADCs (CCAPP, #2N-00-445-1119), CATCs (ACCBC/CAADE, #CP40 872 C 0822), and CAODCs (CADTP, #151). CE credit will be awarded at the conclusion of the training. Partial credit will not be available for those participants who arrive late or leave early.

The Los Angeles County Department of Public Health is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians.

The Los Angeles County Department of Public Health designates this enduring activity for a maximum of 3.00 AMA *PRA Category 1 Credit(s)* $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Filing a Grievance Concerning UCLA ISAP's Continuing Education Program: Please contact Dr. Thomas E. Freese, CE Program Administrator, in writing (UCLA ISAP, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025) or by phone (310-267-5397).

PLEASE NOTE THAT PARKING AT THE SAPC ALHAMBRA CAMPUS COSTS <u>\$5.00</u> PER VEHICLE. WE STRONGLY ENCOURAGE YOU TO CARPOOL. THIS LECTURE IS FREE BUT PRE-REGISTRATION IS REQUIRED.

Please contact Victoria Norith by phone (310) 267-5398 or e-mail (vnorith @mednet.ucla.edu) if you have questions, concerns, special needs, or require additional information before registering for this training.



OR

CLEARLY COMPLETE FORM BELOW AND EMAIL TO VICTORIA (<u>vnorith@mednet.ucla.edu</u>) OR FAX TO 310-312-5398 (ATTN: VICTORIA)







Vaping, Fentanyl, and Methamphetamine, Oh My! A Deep Dive into Emerging Drug Trends Friday, December 13, 2019, 10:00 a.m. – 1:15 p.m.

Complete the following information and fax to 310-312-0538 (ATTN: Victoria) OR e-mail to vnorith@mednet.ucla.edu. PLEASE PRINT <u>CLEARLY</u> IF COMPLETING THE FORM BY HAND! You will receive written CONFIRMATION of your registration or notification that there is no more space available. If you do not receive either of these at least one week prior to the lecture date, please contact Victoria directly at 310-267-5408

FIRST NAME	LAST NAME			
AGENCY				
ADDRESS				
CITY		STATE	ZIP CODE	
PHONE	FAX	E-MA	IL*	
Special Needs or Oth	er Accommodations			
*Would you like to be ad (please check one)?	ded to the Pacific Southwell Yes, please ac	est ATTC listserv to receiv Id me to the listserv		g trainings nank you
Please specify the ty	pe(s) of Continuing Edu	ıcation (CE) credit you	would like to receive:	
□RADT I/II	CADC-CAS	CADC I/II	☐ CADC-CS	CAODC
LAADC	CATC	LMFT/LCSW	LPCC/LEP	CME
Other (Please	Specify):			
License/Certificatio	n Number:			

Funding for this lecture was made possible in part by cooperative agreement 5UR1TI080211-02 from the Substance Abuse and Mental Health Services Administration.